SecBot SecBot
EFFECT ·Filed Apr 6, 2026

IMA

ImageneBio, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC9999999995-26-001080
IPO/offering going effective
Actionable Insight • Neutral

Monitor for future 8-K or 6-K filings announcing actual offering terms. Shelf registrations often precede at-the-market (ATM) offerings or follow-ons, which could pressure shares if significantly dilutive. Given IMA's small $53M market cap, even a modest offering could materially impact the stock.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.55
T+0 close · Apr 6, 2026 · via day close
Latest settled
+26.81%
T+60 · $5.77
Vs SPY
+13.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $4.55entry
  2. T+1 · 7mo ago +4.40%α +4.33% · $4.75
  3. T+5 · 7mo ago +32.97%α +28.83% · $6.05
  4. T+20 · 7mo ago +25.60%α +16.62% · $5.72
  5. T+60 · 5mo ago +26.81%α +13.34% · $5.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImageneBio, Inc. (IMA) has an effective SEC registration (Form S-3) allowing it to sell unspecified securities. This is a shelf registration, not an IPO, meaning the company can now issue shares at any time, creating potential dilution overhang. No offering size, pricing, or use of proceeds details are disclosed in this filing.

Key Facts

  • ImageneBio, Inc. (IMA) has received SEC effectiveness for registration statement 333-290108.
  • This is a shelf registration (S-3), not an IPO, enabling the company to sell securities from time to time.
  • No specific offering size, share count, price, or timing is disclosed in the filing.
  • The effectiveness date was April 3, 2026, with the filing updated on April 6, 2026.
  • The company was formerly known as Ikena Oncology, Inc. (name changed December 8, 2020).

Financial Impact

Undisclosed, potential future dilution depending on offering size and price

dilutionequitymarket cap

Risk Factors

  • Future dilution risk if the company issues equity under this shelf
  • Lack of transparency on offering size or timing creates uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001080
Document: 9999999995-26-001080-index.html9999999995-26-001080
Document: 9999999995-26-001080.txt9999999995-26-001080

Track record

10 reports on IMA

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.94% at T+60 after the Aug 7, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
  2. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
  3. Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
  4. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
  5. Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
  6. Apr 13, 202631w ago 8-K Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
  7. Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
  8. Apr 6, 202632w ago EFFECT Neutral 3/10 Viewing Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
  9. Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
  10. Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026